IGC (IGC Pharma) YoY EPS Growth: -50.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IGC IGC Pharma Inc IGC
24 GF Score
Price $0.28
GF Value $0.23
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma YoY EPS Growth?

IGC Pharma IGC -1.55% 24 YoY EPS Growth is -50.00% as of Jun. 2026. GuruFocus rates IGC with a GF Score™ of 24/100 and a GF Value™ of $0.23 (Modestly Overvalued). The stock has 6 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. IGC Pharma's YoY EPS Growth for the quarter that ended in Jun. 2026 was -50.00%.

IGC Pharma's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.03.

IGC Pharma YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for IGC Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma YoY EPS Growth Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.53 -42.86 26.67 0.00 59.09

IGC Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.33 0.00 50.00 -100.00 -50.00
IGC
24GF Score
IGC Pharma Inc IGC
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

IGC Pharma's YoY EPS Growth for the fiscal year that ended in Mar. 2025 is calculated as:

YoY EPS Growth (A: Mar. 2025 )
=(Earnings per Share (Diluted) (A: Mar. 2025 )-Earnings per Share (Diluted) (A: Mar. 2024 ))/ | Earnings per Share (Diluted) (A: Mar. 2024 ) |
=(-0.09--0.22)/ | -0.22 |
=59.09 %

IGC Pharma's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.03--0.02)/ | -0.02 |
=-50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -50.00% mean?
IGC Pharma (IGC) has a YoY EPS Growth of -50.00% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for IGC Pharma and its competitors.
Is IGC Pharma's YoY EPS Growth too high?
IGC Pharma's current YoY EPS Growth is -50.00%. Overall, IGC Pharma has a GF Score™ of 24/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's YoY EPS Growth compare to ATNM and NNVC?
IGC Pharma's YoY EPS Growth of -50.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for IGC Pharma and its competitors. IGC Pharma's current YoY EPS Growth is -50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.23, compared to a current price of $0.28 — trading 21.1% above its estimated fair value. The current YoY EPS Growth is -50.00%. IGC Pharma's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For IGC Pharma (IGC), the current YoY EPS Growth is -50.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.28 is trading 21.1% above its estimated GF Value™ of $0.23. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for IGC:

  • YoY EPS Growth: -50.00%
  • GF Value™: $0.23 vs. price of $0.28 (21.1% above fair value)
  • GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
24GF Score

Get the complete analysis for IGC

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price
$0.23
GF Value